Meet the six startups that will be working with Shell and Greentown Labs for the next six months. Photo via Greentown

Greentown Labs has named the six participating climatetech startups for an accelerator for a global energy leader.

Shell and Greentown Labs announced the cohort for Greentown Go Make 2023 — a program designed to accelerate partnerships between startups and corporates to advance carbon utilization, storage, and traceability solutions with manufacturing in mind. Shell, which invests in net-zero and carbon-removal technologies, is hoping to strategically align with startups within carbon utilization, storage, and traceability across the energy transition spectrum.

“At Greentown Labs we recognize and appreciate the role energy incumbents must play in the energy transition, and we’re eager to facilitate meaningful partnerships between these impressive startups and Shell—not only to advance these technologies but also to help Shell achieve its sustainability goals,” Kevin Knobloch, CEO and President of Greentown Labs, says in a news release. “We know carbon utilization, storage, and traceability will play a critical role in our collective efforts to reach net-zero, and we’re enthusiastic about the potential impact these companies can have in that work.”

The cohort, selected from 110 applications, is co-located at Greentown's Houston and Somerville, Massachusetts, locations and includes:

  • Portland-based Caravel Bio is developing a novel synthetic biology platform that uses microbial spores and enzymes to create catalysts that are long-lasting and can withstand extreme conditions and environments.
  • Circularise, which is based in the Netherlands, is developing a blockchain platform that provides digital product passports for end-to-end traceability and secure data exchange for industrial supply chains.
  • Corumat, based in Washington, converts organic waste into high-performance, insulating, greaseproof, and biodegradable packaging materials.
  • Cambridge, Massachusetts-headquartered Lydian develops a fully electrified reactor that can convert a variety of gaseous, non-fossil feedstocks into pure syngas with high efficiency.
  • Maple Materials from Richmond, California is developing a low-cost electrolysis process to split carbon dioxide into graphite and oxygen.
  • Ontario, Canada-founded Universal Matter develops a proprietary Flash Joule Heating process that converts carbon waste into high-value and high-performance graphene materials to efficiently create sustainable circular economies.

The program, which includes $15,000 in non-dilutive stipend funding for each company, will work closely with Shell and Greentown over six months via mentorship, networking opportunities, educational workshops, and partnership-focused programming to support collaboration. Go Make 2023 concludes with a showcase event on March 27 at Greentown Labs’ Houston location.

This week, Shell announced another accelerator cohort it's participating in. The Shell GameChanger Accelerator, a partnership with the U.S. Department of Energy’s National Renewable Energy Laboratory (NREL), named four West Coast climatetech companies: DTE Materials, Hexas Biomass, Invizyne Technologies, and ZILA BioWorks. The program provides early-stage cleantech startups with access to experts and facilities to reduce technology development risk and accelerate commercialization of new cleaner technologies.

“Tackling the climate challenge requires multifaceted solutions. At Shell, we believe technology that removes carbon dioxide from the atmosphere will be essential for lowering emissions from energy and chemical products,” Yesim Jonsson, Shell’s GCxN program manager, says in a statement. “The companies in GCxN's sixth cohort embody these objectives and have the potential to usher in a more sustainable future.”

------

This article originally ran on EnergyCapital.

Ad Placement 300x100
Ad Placement 300x600

CultureMap Emails are Awesome

This Houston suburb named one of 10 newest boomtowns in U.S.

Booming 'Burb

What do you get when you combine a city's surge in population, housing growth, and economy? For the Houston suburb of Conroe, it adds up to being America's No. 9 newest boomtown, according to a new survey from SmartAsset.

The personal finance website's just-released report analyzed more than 400 U.S. cities with populations of 65,000 or more to identify places experiencing rapid growth based on five-year changes in economic output, housing units, and labor force size.

Texas is home to the second-highest concentration of new boomtowns in America with 18 out of 75 located in the Lone Star State. Only Florida ranks higher than Texas by just one.

However, Texas nearly locked out the top five most bustling boomtowns in America. Austin suburb Georgetown topped the list, and its Central Texas neighbors New Braunfels (No. 2) and Leander (No. 4) ranked close behind. Dallas-Fort Worth mid-city Lewisville claimed the No. 5 spot. Lehi, Utah ranked in third place.

Conroe has soared in popularity as one of America's most sought-after suburbs over the last several years, boosted by its renter-friendliness and its livability among the millennial generation.

Conroe has seen a 37 percent increase in housing units from 2019 to 2024, with its labor force growing by 33 percent during that time. SmartAsset also determined that Montgomery County's economic output grew at compound annual rates of 4.9 percent.

The report says population booms and "expanding business activity" can create "visible momentum" for an up-and-coming city, but these fast changes can alter a city in ways residents may not expect.

"In recent years, some American cities stand out for attracting people, investment and development at a pace that sets them apart," the report said. "Boomtown status does not mean growth benefits everyone equally, but it does reflect a city’s expanding economic capacity and the new opportunities that come with it."

America's top 10 new boomtowns are:

  • No. 1 – Georgetown
  • No. 2 – New Braunfels
  • No. 3 – Lehi, Utah
  • No. 4 – Leander
  • No. 5 – Lewisville
  • No. 6 – Palm Coast, Florida
  • No. 7 – Nampa, Idaho
  • No. 8 – McKinney
  • No. 9 – Conroe
  • No. 10 – Frisco
---

This article originally appeared on CultureMap.com.

Houston brain health co. secures $6.5M for rare disease study

neuro funding

Houston-based Goldenrod Therapeutics, part of Fannin Partners' portfolio, has announced the initial close of a $6.5 million series seed preferred stock round.

The round was led by Ataxia Ventures and an affiliate of Fannin, according to a news release.

Goldenrod Therapeutics plans to use the funding to support manufacturing, formulation optimization, IND-enabling studies and a Phase I study of its drug to treat brain inflammation, known as 11h.

The study will consider how 11h, which blocks the enzyme PDE4, could treat Friedreich’s ataxia (FA), a rare genetic disease that affects movement, speech and balance. To date, other PDE4 inhibitors have proven to regulate neuroinflammation and neuronal signaling, but have had adverse gastrointestinal side effects or have not reached enough of the central nervous system, according to Goldenrod.

The company says its 11h is expected to have "broad applicability" with limited emetric side effects.

“Our 11h program is a next-generation, orally bioavailable, brain-penetrant PDE4 inhibitor, where researchers overcame longstanding limitations associated with earlier PDE4 inhibitors," Dr. Dev Chatterjee, CEO of Goldenrod, said in the news release. "We believe this creates the potential for a best-in-class therapy for Friedreich’s Ataxia and a potential foundation for development across multiple neurodegenerative and neuroinflammatory disorders.”

11h was first developed at the University of Nebraska Medical Center (UNeMed). Houston-based Fannin Partners in-licensed the product 2020 and landed SBIR Phase I funding to support its initial development for opioid use disorder soon after.

Goldenrod has also received funding to study 11h's effectiveness for multiple sclerosis, methamphetamine addiction and cocaine addiction.

Goldenrod says it is developing 11h to target a variety of neurological and inflammatory conditions, including Alzheimer's disease, multiple sclerosis, ALS, substance use disorders, Batten disease, pain and traumatic brain injury.